Patient characteristics, FOBT1, and CF1
| . | Results . |
|---|---|
| No. of patients | 30 |
| Patient sex | |
| Male/female | 21/9 |
| Median patient age, y (range)* | 59 (29-80) |
| CML status at diagnosis | |
| CP/AP/BC | 30/0/0 |
| Type of TKI | |
| Imatinib/nilotinib/dasatinib | 7/5/18 |
| Prior TKI discontinuation | |
| Y/N | 7/23 |
| Prior TKI reduction | |
| Y/N | 10/20 |
| TKI duration, mo (range)† | 37.5 (2-120) |
| CML status at FOBT1 | |
| CHR/CCyR/MMR/CMR | 1/2/20/7 |
| WBC count at FOBT1, μL (range) | 5770 (2890-14280) |
| Lymphocyte percentage at FOBT1, % (range) | 35.1 (14.8-82.0) |
| Hb level at FOBT1, g/dL (range) | 12.8 (8.2-16.0)‡ |
| Platelet count at FOBT1, ×109/L (range) | 193 (81-297) |
| FOBT1 result | |
| +/− | 10/20 |
| CF1 result | |
| Red flare/erosion/polyp/hemorrhoid | 2/4/3/1 |
| TKI-associated colitis | |
| Y/N | 6/24 |
| . | Results . |
|---|---|
| No. of patients | 30 |
| Patient sex | |
| Male/female | 21/9 |
| Median patient age, y (range)* | 59 (29-80) |
| CML status at diagnosis | |
| CP/AP/BC | 30/0/0 |
| Type of TKI | |
| Imatinib/nilotinib/dasatinib | 7/5/18 |
| Prior TKI discontinuation | |
| Y/N | 7/23 |
| Prior TKI reduction | |
| Y/N | 10/20 |
| TKI duration, mo (range)† | 37.5 (2-120) |
| CML status at FOBT1 | |
| CHR/CCyR/MMR/CMR | 1/2/20/7 |
| WBC count at FOBT1, μL (range) | 5770 (2890-14280) |
| Lymphocyte percentage at FOBT1, % (range) | 35.1 (14.8-82.0) |
| Hb level at FOBT1, g/dL (range) | 12.8 (8.2-16.0)‡ |
| Platelet count at FOBT1, ×109/L (range) | 193 (81-297) |
| FOBT1 result | |
| +/− | 10/20 |
| CF1 result | |
| Red flare/erosion/polyp/hemorrhoid | 2/4/3/1 |
| TKI-associated colitis | |
| Y/N | 6/24 |
AP, accelerated phase; BC, blast crisis; CCyR, complete cytogenetic remission; CHR, complete hematological remission; CMR, complete molecular remission; CP, chronic phase; Hb, hemoglobin; MMR, major molecular remission; WBC, white blood cell; Y/N, yes/no.
Age at FOBT1.
TKI indicates the type of TKI at FOBT1.
No patients revealed clinically significant symptoms.